We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
-1.1%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$8.53B
AUM Growth
+$93.1M
(+1.1%)
Cap. Flow
+$472M
Cap. Flow
% of AUM
5.53%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
812
New
193
Increased
197
Reduced
149
Closed
231
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Analog Devices
ADI
|
+$188M |
| 2 |
AbbVie
ABBV
|
+$121M |
| 3 |
Electronic Arts
EA
|
+$112M |
| 4 |
Autodesk
ADSK
|
+$97.3M |
| 5 |
Keysight
KEYS
|
+$92.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HES
Hess
HES
|
+$123M |
| 2 |
Amphenol
APH
|
+$113M |
| 3 |
Cencora
COR
|
+$108M |
| 4 |
Microsoft
MSFT
|
+$104M |
| 5 |
HP
HPQ
|
+$91.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.52% |
| 2 | Technology | 26.19% |
| 3 | Industrials | 9.44% |
| 4 | Energy | 7.95% |
| 5 | Consumer Discretionary | 5.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
A.O. Smith
AOS
$8.56B
| $7.61M | 0.09% |
115,028
+86,446
| +302% | +$6.14M |
|
252
Pliant Therapeutics
PLRX
$65M
| $7.56M | 0.09% |
436,252
+178,754
| +69% | +$3.1M |
|
253
Phreesia
PHR
$706M
| $7.36M | 0.09% |
+394,082
| New | +$10.6M |
|
254
Endava
DAVA
$154M
| $7.34M | 0.09% |
127,931
+51,871
| +68% | +$2.7M |
|
255
Ultragenyx Pharmaceutical
RARE
$2.54B
| $7.33M | 0.09% |
205,483
-31,081
| -13% | -$1.23M |
|
256
Workiva
WK
$3.38B
| $7.23M | 0.08% |
71,384
-91,091
| -56% | -$9.47M |
|
257
TE Connectivity
TEL
$62.3B
| $7.2M | 0.08% |
+58,324
| New | +$7.8M |
|
258
Granite Ridge Resources
GRNT
$615M
| $7.2M | 0.08% |
+1,180,176
| New | +$8.24M |
|
259
Antero Resources
AR
$10.7B
| $7.15M | 0.08% |
281,861
-606,853
| -68% | -$15.7M |
|
|
VTYX
260
DELISTED
Ventyx Biosciences
VTYX
| $7.08M | 0.08% |
203,783
+53,783
| +36% | +$1.86M |
|
261
Wave Life Sciences
WVE
$1.19B
| $7.06M | 0.08% |
+1,228,683
| New | +$5.61M |
|
262
Qiagen
QGEN
$8.61B
| $6.99M | 0.08% |
162,714
+85,030
| +109% | +$3.96M |
|
263
Flowserve
FLS
$10B
| $6.96M | 0.08% |
+175,117
| New | +$6.76M |
|
264
Vita Coco
COCO
$3.71B
| $6.95M | 0.08% |
266,749
+116,747
| +78% | +$3.12M |
|
265
Leggett & Platt
LEG
$1.31B
| $6.94M | 0.08% |
273,102
+80,376
| +42% | +$2.26M |
|
|
VERV
266
DELISTED
Verve Therapeutics
VERV
| $6.91M | 0.08% |
521,260
+126,839
| +32% | +$2.04M |
|
|
NVRO
267
DELISTED
NEVRO CORP.
NVRO
| $6.85M | 0.08% |
356,285
+183,807
| +107% | +$3.92M |
|
268
Baidu
BIDU
$37.1B
| $6.83M | 0.08% |
+50,843
| New | +$7.13M |
|
269
Ambarella
AMBA
$3.68B
| $6.8M | 0.08% |
+128,309
| New | +$9.01M |
|
270
Allegro MicroSystems
ALGM
$7.91B
| $6.73M | 0.08% |
+210,719
| New | +$8.56M |
|
271
Legend Biotech
LEGN
$3.73B
| $6.72M | 0.08% |
100,000
-69,305
| -41% | -$4.81M |
|
272
PMV Pharmaceuticals
PMVP
$62.9M
| $6.7M | 0.08% |
1,090,740
+357,005
| +49% | +$2.45M |
|
273
Comstock Resources
CRK
$3.88B
| $6.69M | 0.08% |
606,855
-2,017,550
| -77% | -$23.8M |
|
274
Apogee Therapeutics
APGE
$10.2B
| $6.6M | 0.08% |
+310,000
| New | +$6.83M |
|
|
WCN
275
Waste Connections
WCN
$42.2B
| $6.55M | 0.08% |
48,797
-60,004
| -55% | -$8.39M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q3 2023 Portfolio in Review
As of Q3 2023, Woodline Partners held 812 positions worth $8.53B, up 1.1% from $8.44B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Woodline Partners deployed $472M of net new capital in Q3 2023, opening 193 new positions and adding to 197 existing holdings. Its largest new stake was Analog Devices: 1,016,972 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 38% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Hess, an estimated $123M trimmed.
- Woodline Partners's largest Q3 2023 buy was Analog Devices: 1,016,972 shares worth $178M.
- Woodline Partners added most to AbbVie in Q3 2023, an estimated $121M increase.
- Woodline Partners's biggest Q3 2023 reduction was Hess, cutting an estimated $123M.
- Woodline Partners fully exited HP in Q3 2023, selling an estimated $91.2M.
- Woodline Partners's ten largest holdings make up 17% of its $8.53B portfolio in Q3 2023.
- Woodline Partners opened 193 new positions and closed 231 in Q3 2023.
- Woodline Partners's portfolio value rose 1.1% quarter-over-quarter to $8.53B.
Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.